Earnings ·
Geron Corporation reported financial results for the quarter ended June 30, 2026, announcing RYTELO net product…
GERNGeron Corp
Geron Corporation reported financial results for the quarter ended June 30, 2026, announcing RYTELO net product revenue of $57.5 million, an 11% increase from Q1 2026 and a 17% rise year-over-year. The company incurred a net loss of $16.7 million, or $0.02 per share, driven by non-cash inventory-related expenses that increased cost of goods sold to $9.2 million. Geron reiterated its full-year 2026 guidance, expecting RYTELO net product revenue between $220 million and $240 million and total operating expenses between $230 million and $240 million. The firm ended the quarter with approximately $327 million in cash and marketable securities. Additionally, Geron appointed Chinmaya Rath as Chief Business Officer to broaden its leadership team. Geron is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers.